Challenges to participant accrual

The purpose of this study is to find out whether Contrast-Enhanced Mammography/CEM scans performed 2 minutes and 6 minutes after receiving Iohexol contrast dye can be used to identify the amount of residual disease in the breast following neoadjuvant treatment.

Inclusion Criteria:

• Any women >18 years of age at time of informed consent
• Diagnosed with breast cancer and schedule for NAT

Exclusion Criteria:

• History of kidney disease, creatinine level >1.3 or eGFR <45.
• Known allergic reaction to gadolinium or iodinated contrast media.
• Contraindication to contrast-enhanced breast MRI.
• Lesion not included in the field of view of either pre- or post-NAT MRI or CEM
• Presence of pacemakers or automated implantable cardioverter defibrilator
• Pregnant women

Potential research subjects will be identified by a member of the participant's treatment team, the protocol investigator, or research team at Memorial Sloan-Kettering Cancer Center (MSKCC).

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.